Human anaerobic microbiome: a promising and innovative tool in cancer prevention and treatment by targeting pyruvate metabolism

Simple item page
dc.contributor.authorOm, Hari
dc.contributor.authorChand, Umesh
dc.contributor.authorKushawaha, Pramod Kumar
dc.date.accessioned2024-01-21T10:26:46Z
dc.date.accessioned2024-08-13T11:19:33Z
dc.date.available2024-01-21T10:26:46Z
dc.date.available2024-08-13T11:19:33Z
dc.date.issued2023-10-26T00:00:00
dc.description.abstractIntroduction: Even in present-day times, cancer is one of the most fatal diseases. People are overwhelmed by pricey chemotherapy, immunotherapy, and other costly cancer therapies in poor and middle-income countries. Cancer cells grow under anaerobic and hypoxic conditions. Pyruvate is the final product of the anaerobic glycolysis pathway, and many cancer cells utilize pyruvate for their growth and development. The anaerobic microbiome produces many anti-cancer substances that can act as anti-tumor agents and are both feasible and of low cost. There are different mechanisms of action of the anaerobic microbiome, such as the production of short-chain fatty acids (SCFAs), and competition for the anaerobic environment includes the metabolic product pyruvate to form lactic acid for energy. Key findings: In this review, we have summarized the role of the metabolic approach of the anaerobic human microbiome in cancer prevention and treatment by interfering with cancer metabolite pyruvate. SCFAs possess decisive outcomes in condoning almost all the hallmarks of cancer and helping the spread of cancer to other body parts. Studies have demonstrated the impact and significance of using SCFA, which results from anaerobic bacteria, as an anti-cancer agent. Anaerobic bacteria-based cancer therapy has become a promising approach to treat cancer using obligate and facultative anaerobic bacteria because of their ability to penetrate and increase in an acidic hypoxic environment. Significance: This review attempts to provide the interconnection of cancer metabolism and anaerobic microbiome metabolism with a focus on pyruvate metabolism to understand and design unique anaerobic microbiota-based therapy for cancer patients. Graphical abstract: [Figure not available: see fulltext.]. � 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.en_US
dc.identifier.doi10.1007/s00262-023-03551-y
dc.identifier.issn3407004
dc.identifier.urihttp://10.2.3.109/handle/32116/3125
dc.identifier.urlhttps://link.springer.com/10.1007/s00262-023-03551-y
dc.language.isoen_USen_US
dc.publisherSpringer Science and Business Media Deutschland GmbHen_US
dc.subjectAnaerobic glycolysisen_US
dc.subjectAnaerobic microbiomeen_US
dc.subjectCanceren_US
dc.subjectImmunotherapyen_US
dc.subjectPyruvateen_US
dc.subjectSCFAsen_US
dc.titleHuman anaerobic microbiome: a promising and innovative tool in cancer prevention and treatment by targeting pyruvate metabolismen_US
dc.title.journalCancer Immunology, Immunotherapyen_US
dc.typeReviewen_US
dc.type.accesstypeClosed Accessen_US

Files

Collections

Microbiology - Research Publications